F3 and COVID-19: In particular, given that intravascular coagulation and thromboembolism are considered as leading causes of fatality in COVID-19, the application of MSCs remains controversial because variable levels of highly procoagulant tissue factor (TF/CD142) are expressed by MSCs (133).